| INTRODUCTION
Eczema (atopic dermatitis) is a common chronic inflammatory skin disorder that is often seen in early life and affects up to 30% of children worldwide. 1 In addition to social and economic burden associated with the disease, early life eczema has been linked to the subsequent development of asthma and rhinitis, a concept termed "the atopic march". 2, 3 Therefore, eczema is a candidate for a disease-modifying strategy that aims at breaking, stopping, or reversing the course of atopic disease. 4 There is an urgent need for biomarkers that can identify children at increased risk of developing eczema who may substantially benefit from early treatment and preventive strategies.
Eczema is characterized by epidermal barrier defects and immunologic dysregulation. 5, 6 Filaggrin (filament-aggregating protein)
is a major structural protein of the epidermal barrier, and its insufficiency underlies the pathogenesis of eczema. 7, 8 Filaggrin gene (FLG) variants are the strongest and most replicated genetic risk factor for eczema development, in particular for eczema that develops in infancy. [9] [10] [11] Reduced expression of filaggrin in skin of eczema cases compared to controls has been reported. 12, 13 Despite the strong association between FLG genetic variants and eczema, only around 30% of eczema patients carry FLG variants and approximately 10% of eczema cases can be attributed to FLG variants. 1, 10 Hence, FLG variants alone are not sensitive predictors of eczema development. On the other hand, family history of allergic disease and umbilical cord blood (UCB) immunoglobulin E (IgE) levels have been widely speculated as predictors of eczema; however, their predictive value remains controversial. [14] [15] [16] Hence, there is lack of reliable screening biomarker for eczema that identifies individuals at high risk.
Recent studies have shown that epidermal barrier enhancement in early infancy, through application of emollient and moisturizer, is associated with reduced incidence of eczema. 17, 18 Such simple interventions could be applied to children at increased risk of eczema.
Filaggrin, due to its essential role in the formation of the epidermal barrier, is a potential candidate that can serve as a screening biomarker for eczema. Filaggrin is expressed in the skin, oral mucosa, conjunctivae, oesophagus, and cervix, but assessments of its expression in blood cells have been limited. 19, 20 To test the predictive value of a novel biomarker, this study sought to (i) measure expression levels of FLG RNA transcripts in UCB and (ii) assess whether FLG RNA transcripts levels in UCB associate with and predict the development of eczema at ages 3, 6, and 12 months. To achieve the objectives of this study, data from a prospective birth cohort study were analysed.
2 | ME TH ODS 
| Eczema definition
In all assessments (3-, 6-, and 12-month follow-ups), eczema was defined as chronic or chronically relapsing, itchy dermatitis lasting more than 6 weeks with characteristic morphology and distribution, following Hanifin and Rajka criteria. 22 
| FLG genotyping
DNA was extracted from UCB and was genotyped for three FLG null variants common among Europeans: R501X, S3247X, and 2282del4.
Genotyping was performed using TaqMan allelic discrimination assays, 23 with PerfeCTa mastermix (VWR International, Radnor, PA, USA) and 5 ng DNA per sample. Control samples of known genotype were included to allow end-point genotype determination. Individuals carrying the minor allele for at least one of the FLG variants were classified as filaggrin haploinsufficiency. As eczema (the outcome variable) was repeatedly measured at ages 3, 6, and 12 months, generalized estimating equations (GEE)
| FLG gene expression
were applied. 24 First-order autoregressive covariance matrix was implemented to account for correlated repeated measurements when assessing the association between FLG variants and FLG expression with eczema over time (ie, eczema status at ages 3, 6, and 12 months). The GEE approach is a useful method for the analysis of repeated measurements data (longitudinal data), especially when the outcome variable is dichotomous and the repeated outcomes are correlated. The regression coefficient estimates (eg, risk ratio) retuned by the GEE approach are known to be populationaveraged estimates. 24 Hence, as eczema was assessed at ages 3, 6, and 12 months, our interpretations of the GEE estimates will pertain to the first 12 months of life. Also, the GEE approach increases the statistical power due to the fact that all available measurements are analysed. Risk ratios (RR) and their 95% confidence intervals (95% CI) were estimated by applying the modified Poisson regression with robust variance estimation using the GENMOD procedure in SAS 9.4. 25, 26 In all GEE models, sex and age at follow-up were included as potential confounders.
Binary logistic regression models were fitted to assess the ability of FLG expression measured in UCB in predicting (discriminating) those who will (true cases) and will not (true non-cases) develop eczema at ages 3, 6, and 12 months. Receiver operating characteristics (ROC) curves, plotting sensitivity (true positives) by 1-specificity (false positives) at different cut-points, were used to assess the discriminatory performance of models with different predictors. The area under the ROC curve (AUC) was estimated, providing a quantitative summary measure on the discriminatory performance of the fitted models. For instance, a model with AUC of 0.5 has no discrimination value, whereas a model with AUC of 1.0 has perfect discrimination. 27 Area under the curve values and their 95% CIs were estimated using the LOGISTIC procedure in SAS 9.4.
| Sensitivity analysis
To ensure that the predictions models in which AUC was estimated
were not over-fitted and that the estimated AUC was not overestimated, internal cross-validation using the leave-one-out principle was applied. In this cross-validation method, the prediction model is fitted N (number of subjects in the data set) times by dropping the data of one subject and re-estimating the parameter estimates using the rest of the data, producing an overall cross-validated estimate using parameter estimates from the N cross-validation subsets.
3 | RESULTS
| Description of study population
A total of 351 newborns were enrolled and followed up at 3, 6, and 12 months of age. In this report, we focused on 94 participants (analytical study sample) that had information on FLG gene expression and genotypes. The total study sample (n=351) and the analytical sample (n=94) were similar with respect to all characteristics under study ( Table 1 ). The prevalence of eczema was 10.2%, 20.5%, and
16.3% at ages 3, 6, and 12 months, respectively. The combined proportion of carriers of FLG loss-of-function variants R501X, 2282del4, or S3247X was 6.4% (Table 1) .
| FLG variants and eczema risk
The association between FLG variants with eczema at ages 3, 6, and 12 months and the repeated measurements of eczema were evaluated ( Table 2 ). In the repeated measurements analysis, FLG variants were associated with 2.94-fold (95% CI: 1.33-6.51) increased risk of eczema during the first 12 months of life (Table 2 ). In the analytical sample, we have 39 repeated measurements of infants with eczema and 212 repeated measurements without. These will be used in further repeated analyses described as k=39 and k=212.
| Correlations between FLG expression levels
Five probes measuring expression levels of FLG transcripts were available from the genomewide study of gene expression. Spearman correlation coefficients between the five probes were estimated (Table S1 ). There was a robust correlation between transcript levels measured by probes A_32_P387648 (sense transcript) and A_33_P3296200 (antisense transcript) (r=.86, P<.001; Table S1 ). In contrast, correlations between the others probes were weaker (r<.5).
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| FLG variants and FLG expression
Associations were evaluated to determine whether FLG variants influence expression of FLG transcripts ( 
| FLG expression and the future risk of eczema in infancy
The association between FLG expression levels in UCB and the risk of eczema in infancy was analysed using the repeated measurements of eczema (3, 6, and 12 months). Note we have 39 repeated measurements of eczema and 212 measurements without eczema (Table 4 ). In a model adjusted for sex, increased levels of FLG mRNA expression measured by A_24_P51322 were significantly associated with a reduced risk of eczema during the first year of life (RR=0.54, 95% CI: 0.33-0.89, P=.015; 
| Prediction of eczema risk in infancy by FLG expression
The predictive value (discrimination performance) of the two biomarkers (A_24_P51322 and A_21_P0014075) that were significantly associated with eczema was evaluated by estimating the corresponding AUC using different statistical models. In general, AUC estimates were better at predicting eczema at 3 months than at 6 and 12 months of age (Table 5 ). The AUC for discriminating those who will and will not develop eczema at 3 months of age improved Table 5 ).
Hence, our data indicate that models 4 and 8 predict the development of eczema at 3 months with high accuracy.
To ensure that models 4 and 8 (Table 5) Table 5 ). Similarly for model 8, the cross-validated AUC was estimated to be 0.88 (0.79-0.95), which is slightly lower than the na€ ıve AUC estimate of 0.91 (95% CI:
0.84-0.98; Table 5 ). Hence, findings from cross-validation indicate no substantial overestimation of the discriminatory performance of the prediction models. To determine the importance of predicting eczema at 3 months of age, we assessed the extent that eczema at 3 months of age predicts subsequent eczema development. Results of this analysis indicate that 100.0% (9/9) of infants with eczema at 3 months continued to have eczema at 6 months of age (RR=8.25, 95% CI:
| DISCUSSION
3.29-20.67). Similarly, 77.8% (7/9) of infants with eczema at 3 months continued to have eczema at 12 months of age (RR=8.30, 95% CI: 2.67-25.75; data not shown). Hence, eczema at 3 months of age is a strong predictor of subsequent/persistent eczema. Moreover, existing literature demonstrates that early eczema (onset before 2 years) is associated with subsequent/persistent eczema manifestations. 33, 34 Furthermore, it has been widely demonstrated that eczema in infancy is a predictor of subsequent development of rhinitis and asthma. 35, 36 Therefore, developing models that can predict eczema at 3 months of age with high accuracy will guide early stratification and intervention, which could modify the course of the disease in a high-risk population.
Although FLG variants are the strongest and most replicated risk factors for the development of eczema, their value in predicting and explaining the burden of eczema has been limited. 10, 37 This study builds on the evidence that filaggrin expression is modulated, regardless of FLG variants, in eczema patients compared to healthy controls. 12, 38 Such an observation further highlights the importance of this structural protein for the development of functional skin barrier and the pathogenesis of eczema. 39 We demonstrated that the predictive value of FLG expression measured in UCB is slightly improved when FLG genetic variants were added to the prediction models (see Table 5 A recent study found that FLG variants status in mothers increased the risk of eczema in their children, even if the child did not inherit the genetic defect. 40 Therefore, to further corroborate this finding, we ran additional prediction models that included infant FLG expression variable (A_24_P51322 or A_21_P0014075) plus infant sex and maternal FLG variants status; of the 64 mothers with FLG genotype information, 5 (7.8%) carried FLG variants. We compared these results to models that used infant FLG variants status (models 4 and 8; Table 5 We did not find consistent correlation trends between the sense and antisense transcripts (Table S1 ). This may be due, in part, to the genomic physical proximity of the transcripts to each other. For instance, the genomic coordinates of the antisense transcript T A B L E 5 Estimates of area under the receiver operating characteristic curve of models predicting eczema at 3, 6, and 12 mo of age A_33_P3296200 place it closer to the sense transcripts than to the other antisense transcript A_21_P0014075 (Table S2 ). Moreover, due to the observed positive correlations between the antisense transcript A_33_P3296200 with the sense transcripts (Table S1 ), it could be that this antisense transcript is involved in increasing the stability of its target sense mRNA transcripts and thus demonstrating similar expression pattern as the sense transcripts. 41, 42 Whereas, the antisense transcript A_21_P0014075, which did not show correlation with the sense transcripts (Table S1 ), might be a suppressor of transcription initiation or act as a repressor of sense transcription. Therefore, the antisense transcript A_33_P3296200 might be associated with increased filaggrin protein levels, whereas the antisense transcript A_21_P0014075 could be associated with decreased filaggrin protein levels. These proposed explanations are plausible; however, laboratory-based investigation is needed to confirm and determine the precise role of antisense transcripts on filaggrin expression.
The prospective nature of our study and the repeated measurements during the three follow-ups (ages 3, 6, and 12 months) allowed us to assess temporal associations. Moreover, measuring FLG gene expression in UCB and genotyping FLG genetic variants added to the strengths of the current study. To our knowledge, this is the first study that has measured and assessed the association of FLG expression in UCB with eczema in infancy. A limitation of our study is that 94 participants out of the total study sample (n=351) had information on FLG gene expression and FLG genotypes; however, there was no indication of selection (Table 1) . Although the group of infants carrying FLG variants (n=6) is small, the present report focuses on FLG gene expression and only controls for FLG genetic variants. In addition, investigations of the FLG gene expression go beyond the analysis of genetic variants, as some children without FLG haploinsufficiency have a lack of FLG gene expression (Table 3) . Hence, FLG genetic variants are considered to be confounders and not the main exposure in the current study.
FLG gene expression was quantified using an Agilent genomewide microarray (SurePrint G3), which included five probes to measure FLG transcripts. The presence of multiple potential splice sites leading to alternative splicing and thus potentially different RNA transcript isoforms of FLG can be explained by the large and repetitive nature of FLG gene, which also explains the difference between multiple transcription probes. 43 Although the observed associations were clinically and statistically relevant, lack of quantifying the measured transcripts using a polymerase chain reaction (PCR)-based method, which is needed to further validate the microarray measurements, is another limitation to our study. However, searching the Gene Expression Omnibus (GEO) database 44 screening test based on the current prediction models has strong potential to produce high prediction accuracy in future risk of eczema. These findings provide evidence that early identification of infants at increased risk of eczema is possible, which will enable early stratification and intervention to prevent and modify the course of the disease in a high-risk population. Therefore, early identification of the at-risk population with high accuracy and precision coupled with the existence of cost-effective preventive strategies (eg, use of moisturizers and emollients) is a translational step in the research field of eczema that will reduce the associated public health burden.
In conclusion, this study demonstrated, for the first time, the association between FLG gene expression measured in UCB and the risk of subsequent eczema. Moreover, our analysis provided prediction models that were capable of discriminating, to a great extent,
between those who will and will not develop eczema during infancy.
Therefore, future studies measuring FLG expression in UCB and corroborating our findings are needed, and if confirmed, will contribute to early detection of infants at higher risk of eczema who may substantially benefit from early intervention.
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